10:19 AM EST, 12/17/2024 (MT Newswires) -- Ginkgo Bioworks ( DNA ) said Tuesday that it has been awarded a subcontract of up to $9.4 million to develop implantable devices for diagnosing and treating hormone disorders under the Advanced Research Projects Agency for Health's Resilient Extended Automatic Cell Therapies program.

The subcontract is in partnership with Carnegie Mellon University and will focus on bioelectronic cell-based technology, according to the company.

Price: 9.41, Change: -0.02, Percent Change: -0.21